• Vext posted Q1 2026 revenue of USD 12.2 million, up 5.2% year over year; net loss narrowed 73.2% to USD 892,000.
• Gross profit more than doubled to USD 5.5 million, lifting gross margin to 45.4%.
• Adjusted EBITDA climbed 73% sequentially to USD 3.6 million, with the margin widening 14 percentage points to 29%.
• Operating cash flow was USD 1.6 million; cash totaled USD 5.5 million at quarter-end.
• Ohio revenue rose 34% year over year to USD 8.2 million across five operating dispensaries; the Arizona repositioning remained on track with the Eloy cultivation exit underway and targeted for completion by end-Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vext Science Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.